转移性结直肠癌治疗CCMO.pptVIP

* * Here the authors present updated OS data fro the XELOX-1/NO16966 study with an additional 26 months of follow-up compared with the primary analysis. Original 2-arm, open-label study: XELOX (oxaliplatin 130 mg/m2 i.v. day 1 + capecitabine 1000 mg/m2 orally bid days 1?14, every 3 weeks) vs. FOLFOX-4 (oxaliplatin 85 mg/m2 i.v. day 1 + 5-FU 400 mg/m2 i.v. day 1 + LV 200 mg/m2 i.v. day 1). In August 2003, after bevacizumab phase III data became available,5 design was amended to 2x2 partially blinded study by adding bevacizumab 7.5 mg/kg i.v. or placebo on day 1 every 3 weeks to XELOX and bevacizumab 5 mg/kg i.v. or placebo every 2 weeks to FOLFOX-4. The study was double-blind with regard to bevacizumab and placebo administration, but not for Xeloda and 5-FU, since these are administered orally and intravenously, respectively. Recruitment occurred in two phases as the protocol was amended to include a placebo-controlled comparison with bevacizumab. The first phase was an open-label comparison of XELOX vs. FOLFOX-4 only. Cassidy et al. ASCO GI2009 * Overall survival in the different subgroups of the study shows XELOX is non-inferior to FOLFOX-4. Cassidy et al. ASCO GI 2009 * * Overall survival for XELOX /XELOX + placebo / XELOX + bevacizumab vs. FOLFOX-4 / FOLFOX-4 + placebo / FOLFOX-4 + bevacizumab. Cassidy et al. ASCO GI 2009 * * Overall survival for XELOX /XELOX + placebo vs. FOLFOX-4 / FOLFOX-4 + placebo. Cassidy et al. ASCO GI 2009 * * Overall survival for XELOX / XELOX + bevacizumab vs. FOLFOX-4 / FOLFOX-4 + bevacizumab. Cassidy et al. ASCO GI 2009 * * Overall survival for XELOX vs. FOLFOX-4. Cassidy et al. ASCO GI 2009 * This table summarises the adverse events of interest, together with severity, for XELOX and FOLFOX-4. Cassidy et al. ASCO GI 2009 * This figure summarises the most common grade 3/4 treatment-related adverse events for XELOX and FOLFOX-4. Cassidy et al. ASCO GI 2009 * This 26-month update confirms that XELOX is non-inferior to FOLFOX-4 as first-